Humana (NYSE:HUM) PT Lowered to $381.00

Humana (NYSE:HUM) had its price objective lowered by research analysts at Jefferies Financial Group from $411.00 to $381.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the insurance provider’s stock. Jefferies Financial Group’s price target would suggest a potential upside of 16.22% from the company’s previous close.

A number of other brokerages also recently commented on HUM. The Goldman Sachs Group lowered their price objective on Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research report on Wednesday, April 3rd. StockNews.com lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 26th. Mizuho lowered their target price on shares of Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, January 26th. Cantor Fitzgerald reissued a “neutral” rating and issued a $391.00 target price on shares of Humana in a report on Wednesday, April 10th. Finally, Bank of America reaffirmed a “neutral” rating and set a $342.00 price target (down from $470.00) on shares of Humana in a report on Tuesday, April 2nd. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average target price of $454.63.

Humana Price Performance

Humana stock opened at $327.84 on Monday. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana has a 52-week low of $299.23 and a 52-week high of $541.21. The firm has a market cap of $39.55 billion, a PE ratio of 16.54, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The company’s 50 day moving average is $329.86 and its two-hundred day moving average is $398.38.

Humana (NYSE:HUM) last posted its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). The company had revenue of $26.46 billion for the quarter, compared to analysts’ expectations of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The firm’s revenue was up 17.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.62 EPS. On average, research analysts expect that Humana will post 16.06 EPS for the current fiscal year.

Insider Transactions at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.29% of the company’s stock.

Hedge Funds Weigh In On Humana

Institutional investors have recently bought and sold shares of the company. Ronald Blue Trust Inc. increased its stake in shares of Humana by 26.8% during the third quarter. Ronald Blue Trust Inc. now owns 189 shares of the insurance provider’s stock worth $84,000 after acquiring an additional 40 shares during the period. B & T Capital Management DBA Alpha Capital Management raised its stake in shares of Humana by 7.1% during the 3rd quarter. B & T Capital Management DBA Alpha Capital Management now owns 7,463 shares of the insurance provider’s stock worth $3,631,000 after buying an additional 496 shares in the last quarter. Meridian Wealth Management LLC lifted its holdings in shares of Humana by 71.3% in the 3rd quarter. Meridian Wealth Management LLC now owns 6,912 shares of the insurance provider’s stock valued at $3,363,000 after buying an additional 2,876 shares during the period. Exchange Traded Concepts LLC boosted its stake in shares of Humana by 103.0% in the third quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock valued at $1,403,000 after buying an additional 1,463 shares in the last quarter. Finally, Caprock Group LLC boosted its stake in shares of Humana by 3.6% in the third quarter. Caprock Group LLC now owns 1,421 shares of the insurance provider’s stock valued at $693,000 after buying an additional 50 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.